Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChallengerASX:CGF -2.19%62 Days Sales Outstanding is 161.74 as of Jun. 2026, which is 21% above its 10-year median of 133.21. GuruFocus rates ASX:CGF with a GF Score™ of 62/100 and a GF Value™ of A$5.71 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 60 Insurance companies, Challenger ranks worse than 88.33% on this metric.
Challenger's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$727 Mil. Challenger's Revenue for the
six
months ended in Jun. 2026 was A$820 Mil.
Hence, Challenger's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 161.74.
The historical rank and industry rank for Challenger's Days Sales Outstanding or its related term are showing as below:
ASX:CGF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.2 Med: 133.21 Max: 261.58
Current: 143.18
During the past 13 years, Challenger's highest Days Sales Outstanding was 261.58. The lowest was 54.20. And the median was 133.21.
ASX:CGF's Days Sales Outstanding is ranked worse than 88.33% of 60
companies
in the Insurance industry
Industry Median: 48.32
vs ASX:CGF: 143.18
Challenger's Days Sales Outstanding
increased
from Jun. 2025 (119.37) to Jun. 2026 (161.74).
Challenger (ASX:CGF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Challenger Days Sales Outstanding Related Terms
Challenger Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Challenger's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CGF vs MET, AFL, PRU: Days Sales Outstanding Comparison
For the Insurance - Life subindustry, Challenger's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Challenger Days Sales Outstanding vs Insurance Industry
For the Insurance industry and Financial Services sector, Challenger's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Challenger's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 161.74 mean?
Challenger (ASX:CGF) has a Days Sales Outstanding of 161.74 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Challenger and its competitors. This is 21% above median its historical median of 133.21. Over the past decade, Challenger's Days Sales Outstanding has ranged from 54.20 to 261.58. According to the industry distribution chart, Challenger ranks #53 out of 60 companies in the Insurance industry, placing it in the top 88.3%.
Is Challenger's Days Sales Outstanding too high?
Challenger's current Days Sales Outstanding of 161.74 is 21% above median its 10-year median of 133.21. Over the past 10 years, this metric has ranged from a low of 54.20 to a high of 261.58. The Insurance industry median Days Sales Outstanding is 48.32. Challenger's value of 161.74 is 234.7% above this industry median. Based on the distribution chart, Challenger ranks #53 out of 60 companies in the Insurance industry, which is in the bottom quartile relative to peers. Overall, Challenger has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Challenger's Days Sales Outstanding compare to MET and AFL?
According to the Insurance industry distribution chart, Challenger ranks #53 out of 60 companies for Days Sales Outstanding. This places Challenger in the lower half of its industry. The industry median Days Sales Outstanding is 48.32. Challenger's value of 161.74 is 234.7% above this benchmark. Historically, Challenger's own Days Sales Outstanding has ranged from 54.20 to 261.58 over the past decade. While the company's 10-year median is 133.21 vs. the industry median of 48.32, Challenger has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for an Insurance company?
The median Days Sales Outstanding among Insurance companies is 48.32, based on 60 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Challenger's current Days Sales Outstanding of 161.74 is 234.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Challenger and its competitors. For the Insurance industry, the median Days Sales Outstanding is 48.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Challenger's current Days Sales Outstanding is 161.74, which is 21% above median its own 10-year median of 133.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Challenger stock overvalued right now?
Based on GuruFocus' analysis, Challenger (ASX:CGF) is currently considered Significantly Overvalued. The stock's GF Value™ is A$5.71, compared to a current price of A$9.38 — trading 64.3% above its estimated fair value. The current Days Sales Outstanding is 161.74, which is 21% above median its 10-year median of 133.21 and 234.7% above the Insurance industry median of 48.32. Challenger's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Challenger (ASX:CGF), the current Days Sales Outstanding is 161.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Challenger (ASX:CGF) Overvalued in 2026?
Based on GuruFocus' analysis, Challenger stock appears to be overvalued.
The current stock price of A$9.38 is trading 64.3% above its estimated GF Value™ of A$5.71.
GuruFocus considers Challenger to be Significantly Overvalued.
Key valuation signals for ASX:CGF:
Days Sales Outstanding: 161.74 (21% above median its 10-year median of 133.21)
GF Value™: A$5.71 vs. price of A$9.38 (64.3% above fair value)
Industry Position: 234.7% above the Insurance median (#53 of 60)
No single metric tells the full story. See the ASX:CGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Challenger's core business is selling annuity products in the Australian retirement market and, since November 2016, selling Australian dollar-denominated annuities into Japan's large retirement market. The firm's annuity products provide investors guaranteed regular payments over an agreed term for an upfront lump sum investment and is designed primarily to protect investors from the longevity risk of outliving their savings. Challenger also operates a funds management business, Fidante Partners, which has minority stakes in several boutique global investment managers, and Challenger Investment Management, which primarily manages investments supporting its annuities business.
62GF Score
Get the complete analysis for ASX:CGF
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGF has been successfully added to your 
